MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Disease-modifying strategies"

  • 2025 International Congress

    Neuroprotective Role of Diosgenin-Loaded Lipid Nanoparticles for Parkinson’s Disease: Pharmacokinetic and Pharmacodynamic Insights

    R. Rajput, S. Verma (Agra, India)

    Objective: To develop, optimize, and evaluate diosgenin-loaded solid lipid nanoparticles (DG-SLNs) and nanostructured lipid carriers (DG-NLCs) incorporated into hydrogel formulations (DG-SLN-C and DG-NLC-C) for improved…
  • 2025 International Congress

    Peripheral insulin resistance may predict exenatide treatment response in Parkinson’s disease

    N. Vijiaratnam, C. Girges, J. Dickson, C. Caroll, M. Silverdale, M. Hu, G. Duncan, K. Chaudhuri, S. Gandhi, D. Athauda, Y. Li, N. Greig, K. Chowdhury, T. Foltynie (London, United Kingdom)

    Objective: To explore if the glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide could modify the course of Parkinson’s disease (PD) and if peripheral insulin resistance (IR) mightdifferentially impact on this. Background: Exenatide…
  • 2025 International Congress

    Therapeutic Efficacy of Human Dental Pulp Stem Cells-Derived Exosome-Encased Phloroglucinol In MPTP-Induced Chronic Parkinsonian Rat model: Potential for Disease Modification

    I. Datta, K. Mondal, R. Ghanty, G. Wagmare, A. Mahadevan, R. Santhoshkumar, N. Bn (Bengaluru, India)

    Objective: This study aimed to evaluate the therapeutic efficacy of intranasally administered exosome-encased phloroglucinol (Exo-Phl) in a MPTP rat model of PD. Background: Dopaminergic (DA)…
  • 2025 International Congress

    Cognitive and Motor Wobbling in Isolated RBD: A Multicentric Study by the International RBD Study Group (IRBDSG)

    A. Stefani, S. Joza, D. Arnaldi, L. Baldelli, G. Benbir, B. Boeve, V. de Cock, L. Churchill, B. Högl, M. Hu, B. Huang, R. Kim, K. Kufer, J-Y. Lee, C. Liguori, B. Mollenhauer, L. Muntean, N. Li, B. Orso, M. Patyjewicz, R. Postuma, F. Provini, S. Lewis, C. Simonet, M. Sommerauer, A. Videnovic, Y. Wing, C. Trenkwalder (Innsbruck, Austria)

    Objective: To define and characterize clinically fluctuating transition phases from isolated RBD (iRBD) to overt alpha-synucleinopathy. Background: Patients with iRBD often develop motor and non-motor…
  • 2025 International Congress

    Beyond Medication: The Potential of Diet in Parkinson’s Management

    G. Hitawala, L. Shulman (Baltimore, USA)

    Objective: To assess the effects of diet and dietary supplements on motor/non-motor symptoms, and disease progression in Parkinson disease (PD). Background: Diet has generally played…
  • 2025 International Congress

    A multi-center, randomized, controlled study of the add-on effect of selegiline or zonisamide to L-dopa/DCI therapy in Parkinson’s disease (DATSZ-PD study)

    M. Takahashi, J. Koh, T. Shimokawa, Y. Kajimoto, T. Takeshima, H. Ito (Hirakata, Osaka, Japan)

    Objective: To investigate the efficacy and safety for neuroprotection and disease modifying effect in  selegiline(SL) or zonisamide(ZN) by using UPDRS, PDQ-39 and DAT -SPECT  in…
  • 2025 International Congress

    A Novel Therapeutic Targeting the tPA-NMDAr Interaction for Parkinson’s Disease

    M. Blanc, E. Su, D. Torrente, B. Zhang, D. Vivien, F. Lesept, N. Deletage (Lyon & Caen, France)

    Objective: Glunomab, a monoclonal antibody designed to inhibit the interaction between tissue plasminogen activator (tPA) and the N-methyl-D-aspartate receptor (NMDAr), has demonstrated therapeutic potential across…
  • 2025 International Congress

    Prodromal Parkinson’s Disease in Agent Orange Exposed US Vietnam Veterans

    E. Uc, C. Weber, M. Lenz, J. Dawson (Iowa City, USA)

    Objective: 1-Comparing the risk of prodromal PD between AO exposed veterans (AOEV) and non-AO exposed veterans without PD (Controls) in a Veterans Affairs (VA) hospital…
  • 2025 International Congress

    VGN-R09b, an Adeno-associated virus-based Combination Gene Replacement Therapy for Parkinson’s Disease

    YZ. Tao, SS. Tian, L. Lu, X. Zhu, H. Lv, XP. Zhao (Shanghai, China)

    Objective: Develop a sustained disease modifying gene therapy for treating Parkinson’s disease Background: Parkinson’s disease (PD) is characterized by the progressive loss of dopaminergic neurons…
  • 2025 International Congress

    Educational Strategies for Enhancing Caregiver Knowledge and Capacities in Parkinson’s Disease Management: A Comprehensive Review

    S. A. Hassan, S. Abozeid, Y. M.HUSSEINY, H. Abdelbar, S. Elrobeigi, M. M. Elsayed (Giza, Egypt)

    Objective: To evaluate the effectiveness of educational strategies in enhancing caregiver knowledge, skills, and confidence in managing Parkinson’s disease (PD) and to identify gaps in…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley